Previously submitted to: JMIR Public Health and Surveillance (no longer under consideration since Feb 14, 2023)
Date Submitted: Aug 16, 2022
Open Peer Review Period: Aug 16, 2022 - Aug 30, 2022
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Prevalence and determinants of completing primary COVID-19 vaccination series among cancer patients in China: a multicentre cross-sectional survey
ABSTRACT
Background:
Cancer patients have higher risk of contracting COVID-19 and are more vulnerable to severe consequences of COVID-19 infection. COVID-19 vaccination is effective for cancer patients without safety concerns. However, COVID-19 vaccination hesitancy is common among cancer patients.
Objective:
This study investigated the prevalence of completing primary COVID-19 vaccination series among cancer patients in China. We examined the effects of sociodemographic data, characteristics of cancer and treatment, and factors at individual level (perceptions) and interpersonal level (media influence).
Methods:
A multicentre cross-sectional study was conducted in four Chinese cities (Changzhi, Hohhot, Urumqi, and Shenzhen) in different geographic regions between May and June 2022. Medical staff of the collaborative hospitals invited all cancer inpatients aged 18 years or above without lymphoma or leukaemia to complete a face-to-face survey. A total of 893 provided written informed consent and completed the study. Logistic regression models were fitted.
Results:
Among the participants, 58.8% completed the primary COVID-19 vaccination series. Among vaccinated participants, 13.8% reported some side effects. The most common side effect was pain in the injection site (9.3%); no severe side effects were reported. After adjusting for significant background characteristics, perceived higher risk of COVID-19 infection comparing to people without cancers (adjusted odds ratios [AOR]: 0.46, 95%CI: 0.24, 0.88), perceived a high chance of having severe consequences of COVID-19 infection (AOR: 0.68, 95%CI: 0.51, 0.91), and concerns about interactions between COVID-19 vaccination and cancers/cancer treatments (AOR: 0.97, 95%CI: 0.94, 0.99) were associated with lower completion of primary vaccination series. Being suggested by significant others (AOR: 1.32, 95%CI: 1.23, 1.41) and perceived higher self-efficacy to receive COVID-19 vaccination (AOR: 1.48, 95%CI: 1.31, 1.67) were positively associated with the dependent variable.
Conclusions:
Completion rate of primary COVID-19 vaccination series was low among Chinese cancer patients. Given the large population size and their vulnerability, there is an urgent need to increase COVID-19 vaccination coverage in this group. Removing concerns about interactions between COVID-19 vaccination and cancers/cancer treatments, using fear appeal approach, involving significant others, and facilitating patients to make a plan to receive COVID-19 vaccination might be useful strategies.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.